• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

瑞士3T3细胞中DNA拓扑异构酶II的生长状态和细胞周期依赖性磷酸化

Growth state and cell cycle dependent phosphorylation of DNA topoisomerase II in Swiss 3T3 cells.

作者信息

Saijo M, Ui M, Enomoto T

机构信息

Department of Physiological Chemistry, Faculty of Pharmaceutical Sciences, University of Tokyo, Japan.

出版信息

Biochemistry. 1992 Jan 21;31(2):359-63. doi: 10.1021/bi00117a007.

DOI:10.1021/bi00117a007
PMID:1310036
Abstract

We have investigated the amount of DNA topoisomerase II and phosphorylation of the enzyme in Swiss 3T3 cells during the transition from cell quiescence to proliferation. A relatively high level of phosphorylation was observed with proliferating cells while no or a very low level of phosphorylation was observed with quiescent cells. Phosphoamino acid analysis of the phosphorylated topoisomerase II revealed that the phosphorylated aminoacyl residue was serine. When quiescent cells were stimulated to grow by the addition of serum, DNA synthesis began to increase at 9 h after serum addition, reaching a maximum at 15 h and then declining. The amount of topoisomerase II began to increase at 6 h and reached a maximum at 22-27 h, corresponding to the G2 phase. The phosphorylation of topoisomerase II measured by pulse-labeling gradually increased from 6 to 18 h and reached a maximum at 22 h when the amount of the enzyme was maximum. The level of phosphorylation measured by continuous-labeling increased gradually up to 12 h and markedly up to 28 h, and then declined. The increase in the rate of phosphorylation in the G2 phase was affected by inhibiting DNA synthesis, but the increase in the amount of the enzyme was not. Thus, it was suggested that the regulation of phosphorylation of topoisomerase II differs from that of the amount of the enzyme.

摘要

我们研究了瑞士3T3细胞从静止状态转变为增殖状态过程中DNA拓扑异构酶II的含量及其磷酸化情况。增殖细胞中观察到相对较高水平的磷酸化,而静止细胞中未观察到或仅有非常低水平的磷酸化。对磷酸化拓扑异构酶II进行的磷酸氨基酸分析表明,磷酸化的氨酰基残基是丝氨酸。当通过添加血清刺激静止细胞生长时,DNA合成在添加血清后9小时开始增加,在15小时达到最大值,然后下降。拓扑异构酶II的含量在6小时开始增加,在22 - 27小时达到最大值,对应于G2期。通过脉冲标记测量的拓扑异构酶II的磷酸化从6小时到18小时逐渐增加,在22小时酶含量达到最大值时达到峰值。通过连续标记测量的磷酸化水平在12小时前逐渐增加,在28小时显著增加,然后下降。G2期磷酸化速率的增加受到DNA合成抑制的影响,但酶含量的增加不受影响。因此,提示拓扑异构酶II磷酸化的调节与酶含量的调节不同。

相似文献

1
Growth state and cell cycle dependent phosphorylation of DNA topoisomerase II in Swiss 3T3 cells.瑞士3T3细胞中DNA拓扑异构酶II的生长状态和细胞周期依赖性磷酸化
Biochemistry. 1992 Jan 21;31(2):359-63. doi: 10.1021/bi00117a007.
2
Topoisomerase-specific drug sensitivity in relation to cell cycle progression.
Mol Cell Biol. 1987 Sep;7(9):3119-23. doi: 10.1128/mcb.7.9.3119-3123.1987.
3
Growth state- and cell cycle-dependent fluctuation in the expression of two forms of DNA topoisomerase II and possible specific modification of the higher molecular weight form in the M phase.两种形式的DNA拓扑异构酶II表达的生长状态和细胞周期依赖性波动以及M期高分子量形式的可能特异性修饰。
J Biol Chem. 1994 Jan 14;269(2):1173-6.
4
Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells.
Cancer Res. 1988 Jun 1;48(11):3230-5.
5
Role of proliferation in determining sensitivity to topoisomerase II-active chemotherapy agents.增殖在决定对拓扑异构酶II活性化疗药物敏感性中的作用。
NCI Monogr. 1987(4):73-8.
6
Cell cycle-coupled relocation of types I and II topoisomerases and modulation of catalytic enzyme activities.I型和II型拓扑异构酶的细胞周期偶联重定位及催化酶活性的调节
J Cell Biol. 1997 Feb 24;136(4):775-88. doi: 10.1083/jcb.136.4.775.
7
Cell-cycle-dependent phosphorylation and activity of Chinese-hamster ovary topoisomerase II.中国仓鼠卵巢细胞拓扑异构酶II的细胞周期依赖性磷酸化及活性
Biochem J. 1993 Jul 1;293 ( Pt 1)(Pt 1):297-304. doi: 10.1042/bj2930297.
8
DNA topoisomerase I and II activities during cell proliferation and the cell cycle in cultured mouse embryo fibroblast (C3H 10T1/2) cells.
Exp Cell Res. 1985 May;158(1):1-14. doi: 10.1016/0014-4827(85)90426-4.
9
Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells.增殖依赖性拓扑异构酶II含量作为人、小鼠和中国仓鼠卵巢细胞中抗肿瘤药物作用的决定因素。
Cancer Res. 1987 Aug 1;47(15):3973-9.
10
Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells.
Cell Growth Differ. 1991 Apr;2(4):209-14.

引用本文的文献

1
Mitotic chromosomes.有丝分裂染色体。
Semin Cell Dev Biol. 2021 Sep;117:7-29. doi: 10.1016/j.semcdb.2021.03.014. Epub 2021 Apr 6.
2
Mechanisms regulating resistance to inhibitors of topoisomerase II.调控拓扑异构酶 II 抑制剂耐药性的机制。
Front Pharmacol. 2013 Aug 1;4:89. doi: 10.3389/fphar.2013.00089. eCollection 2013.
3
Type II topoisomerase activities in both the G1 and G2/M phases of the dinoflagellate cell cycle.在甲藻细胞周期的G1期和G2/M期的II型拓扑异构酶活性。
Chromosoma. 2005 Dec;114(6):420-31. doi: 10.1007/s00412-005-0027-3. Epub 2005 Nov 15.
4
Extracellular signal-regulated kinase activates topoisomerase IIalpha through a mechanism independent of phosphorylation.细胞外信号调节激酶通过一种独立于磷酸化的机制激活拓扑异构酶IIα。
Mol Cell Biol. 1999 May;19(5):3551-60. doi: 10.1128/MCB.19.5.3551.
5
Cell cycle-coupled relocation of types I and II topoisomerases and modulation of catalytic enzyme activities.I型和II型拓扑异构酶的细胞周期偶联重定位及催化酶活性的调节
J Cell Biol. 1997 Feb 24;136(4):775-88. doi: 10.1083/jcb.136.4.775.
6
A topoisomerase II-like protein is part of an inducible DNA-binding protein complex that binds 5' of an immunoglobulin promoter.一种拓扑异构酶II样蛋白是一种可诱导的DNA结合蛋白复合物的一部分,该复合物结合在免疫球蛋白启动子的5'端。
Nucleic Acids Res. 1993 Sep 11;21(18):4363-8. doi: 10.1093/nar/21.18.4363.
7
Cell-cycle-dependent phosphorylation and activity of Chinese-hamster ovary topoisomerase II.中国仓鼠卵巢细胞拓扑异构酶II的细胞周期依赖性磷酸化及活性
Biochem J. 1993 Jul 1;293 ( Pt 1)(Pt 1):297-304. doi: 10.1042/bj2930297.
8
In vitro assessment of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance.N-[2-(二甲基氨基)乙基]吖啶-4-甲酰胺的体外评估,一种对多药耐药性敏感性降低的DNA嵌入型抗肿瘤药物。
Cancer Chemother Pharmacol. 1993;31(5):401-6. doi: 10.1007/BF00686155.
9
Cytokinetic differences in the action of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide as compared with that of amsacrine and doxorubicin.与安吖啶和多柔比星相比,N-[2-(二甲氨基)乙基]吖啶-4-羧酰胺作用中的细胞动力学差异。
Cancer Chemother Pharmacol. 1993;32(6):463-70. doi: 10.1007/BF00685891.
10
The C-terminal domain of Saccharomyces cerevisiae DNA topoisomerase II.酿酒酵母DNA拓扑异构酶II的C末端结构域。
Mol Cell Biol. 1994 May;14(5):3197-207. doi: 10.1128/mcb.14.5.3197-3207.1994.